Related references
Note: Only part of the references are listed.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Laura Dickinson et al.
CLINICAL PHARMACOKINETICS (2016)
Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment
Andrea Calcagno et al.
AIDS (2016)
CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women
Carola R. Roehrich et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments
Gianluca Russo et al.
INFECTION GENETICS AND EVOLUTION (2016)
Efavirenz pharmacogenetics in a cohort of Italian patients
Jessica Cusato et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants
Kiyoto Tsuchiya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)
Jose R. Castillo-Mancilla et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals
Catalina Barcelo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Influence of ABCC2 and ABCC4 Polymorphisms on Tenofovir Plasma Concentrations in Thai HIV-Infected Patients
Kanokrat Rungtivasuwan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study
Anne F. Luetkemeyer et al.
CLINICAL INFECTIOUS DISEASES (2015)
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study
L. Dickinson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)
S. Bonora et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Class-specific relative genetic contribution for key antiretroviral drugs
Marco Siccardi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study
Janaki Amin et al.
LANCET INFECTIOUS DISEASES (2015)
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism
C. Sukasem et al.
INFECTION (2014)
Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants
Kiyoto Tsuchiya et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
Fred S. Sarfo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis
Andrea Calcagno et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
Antonio D'Avolio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes
David W. Haas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202
Daniel H. Johnson et al.
PHARMACOGENETICS AND GENOMICS (2014)
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction
Andrea Calcagno et al.
PHARMACOGENOMICS (2014)
Induction of P-Glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells
Gary N. Y. Chan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors
A. Calcagno et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
Eliford Ngaimisi et al.
PLOS ONE (2013)
Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Sarah C. Preissner et al.
PLOS ONE (2013)
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
Rubin Lubomirov et al.
PHARMACOGENETICS AND GENOMICS (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
Claudia P. Cortes et al.
THERAPEUTIC DRUG MONITORING (2013)
Discordant Associations Between SLCO1B1 521T → C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146
Xinyan Zhang et al.
THERAPEUTIC DRUG MONITORING (2013)
A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir
Deidre A. Kile et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults
Alessandro Schipani et al.
ANTIVIRAL THERAPY (2012)
PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
Marelize Swart et al.
BMC MEDICAL GENETICS (2012)
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults
Chonlaphat Sukasem et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices
Andrea Calcagno et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
M. Viljoen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1-Infected Children in Rwanda: Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms
Philippe R. Mutwa et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Influence of SLCO1B1 Polymorphisms on the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin
Christina L. Aquilante et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians
Julie Bertranda et al.
PHARMACOGENETICS AND GENOMICS (2012)
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
Neill J. Liptrott et al.
PHARMACOGENETICS AND GENOMICS (2012)
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
Kevin C. Brown et al.
PHARMACOGENOMICS (2012)
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals
Sandra G. Heil et al.
THERAPEUTIC DRUG MONITORING (2012)
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients
Marelize Swart et al.
Frontiers in Genetics (2012)
Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat
Roxana N. Peroni et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
Alessandro Schipani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients
Abiy Habtewold et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction
Sudeep P. Pushpakom et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine
Thorsten Lehr et al.
PHARMACOGENETICS AND GENOMICS (2011)
CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children
Natella Y. Rakhmanina et al.
THERAPEUTIC DRUG MONITORING (2011)
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Hassane Izzedine et al.
AIDS (2010)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Alessandro Schipani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men
Fabiana B. Kohlrausch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Nuclear Receptor-Mediated Induction of CYP450 by Antiretrovirals: Functional Consequences of NR1I2 (PXR) Polymorphisms and Differential Prevalence in Whites and Sub-Saharan Africans
Jenny Svaerd et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Ruben C. Hartkoorn et al.
PHARMACOGENETICS AND GENOMICS (2010)
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
Laure Elens et al.
PHARMACOGENOMICS (2010)
CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients
Jun Chen et al.
THERAPEUTIC DRUG MONITORING (2010)
Presence of the CYP2B6 516G > T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
Verena Gounden et al.
AIDS RESEARCH AND THERAPY (2010)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
Jackson K. Mukonzo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications
P. Kannan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
L. A. Wenning et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
T. W. Mahungu et al.
HIV MEDICINE (2009)
Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
David W. Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Pharmacogenetics of tenofovir treatment
Sonia Rodriguez-Novoa et al.
PHARMACOGENOMICS (2009)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme
Hongbing Wang et al.
CURRENT DRUG METABOLISM (2008)
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HN-Infected patients
Jennifer J. Kiser et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: Case report and review of the literature
Mauro S. Torno et al.
PHARMACOTHERAPY (2008)
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
J. J. Kiser et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection
Jennifer J. Kiser et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
Hiroyuki Gatanaga et al.
CLINICAL INFECTIOUS DISEASES (2007)
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
Akihiko Saitoh et al.
AIDS (2007)
Polymorphic CYP2B6:: molecular mechanisms and emerging clinical significance
Ulrich M. Zanger et al.
PHARMACOGENOMICS (2007)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Zeruesenay Desta et al.
PHARMACOGENOMICS (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Cytochrome P4502B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda
S. R. Penzak et al.
HIV MEDICINE (2007)
Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study
Alison A. Motsinger et al.
PHARMACOGENETICS AND GENOMICS (2006)
Orosomucoid (α1-acid glycoprotein) plasma concentration and genetic variants:: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation
Sara Colombo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study
Peter L. Anderson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study
HJ Ribaudo et al.
CLINICAL INFECTIOUS DISEASES (2006)
Comparative pharmacogenomics of antiretroviral and cytotoxic treatments
J Stebbing et al.
LANCET ONCOLOGY (2006)
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy
C Verstuyft et al.
AIDS (2005)
Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
DW Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
S Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2005)
Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver
A Owen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
K Tsuchiya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance
C Marzolini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture
E Störmer et al.
PHARMACEUTICAL RESEARCH (2002)
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
J Fellay et al.
LANCET (2002)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Share Paper
